PL3.3 Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion
Martin J. van den Bent(Erasmus MC Cancer Institute), Pim J. French(Erasmus MC Cancer Institute), Anna K. Nowak(The University of Western Australia), Michael Weller(University Hospital of Zurich), Jean‐François Baurain(Cliniques Universitaires Saint-Luc), Pieter Wesseling(Radboud University Nijmegen), W. P. Mason(Cliniques Universitaires Saint-Luc), Sara Erridge(The University of Texas MD Anderson Cancer Center), Kenneth Aldape(National Institutes of Health), Helen Wheeler(The University of Sydney), Marc Sanson(Centre National de la Recherche Scientifique), C. Mircea S. Tesileanu(Erasmus MC Cancer Institute), Brigitta G. Baumert(Kantonsspital Graubünden), Wolfgang Wick(German Cancer Research Center), Alba A. Brandes(Istituto delle Scienze Neurologiche di Bologna), J. M. Kros(Erasmus MC), V. Golfinopoulos(Universitat de València), Paul M. Clément(Universitair Ziekenhuis Leuven), Michael A. Vogelbaum(Moffitt Cancer Center), T. Gorlia(Roche (Switzerland))
Cited by 29
Related Papers
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Pan-cancer analysis of whole genomes
|Nature|2020|3.3k
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
|New England Journal of Medicine|2014|2.8k
Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study
|Journal of Clinical Oncology|2010|2k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k